{"id":"ursodeoxycholic-acid-capsules","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Diarrhea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-15","effect":"Pruritus"},{"rate":"3-8","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ursodeoxycholic acid (UDCA) is a naturally occurring hydrophilic bile acid that decreases the cholesterol content of bile and promotes its flow through the biliary system. It protects hepatocytes from cytotoxic bile acids and has immunomodulatory properties that reduce inflammation in the liver. These mechanisms make it effective in treating cholestatic liver diseases by improving bile flow and reducing hepatic injury.","oneSentence":"Ursodeoxycholic acid is a bile acid that reduces cholesterol saturation in bile and increases bile flow to improve hepatic function and reduce cholestasis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:18.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary biliary cholangitis (PBC)"},{"name":"Primary sclerosing cholangitis (PSC)"},{"name":"Cholestasis of pregnancy"},{"name":"Gallstone dissolution"}]},"trialDetails":[{"nctId":"NCT07477782","phase":"PHASE2","title":"Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05","conditions":"Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD)","enrollment":72},{"nctId":"NCT03724175","phase":"PHASE2, PHASE3","title":"The Role of Secondary Bile Acids in Intestinal Inflammation","status":"TERMINATED","sponsor":"Stanford University","startDate":"2019-08-26","conditions":"Ulcerative Colitis, Pouchitis","enrollment":2},{"nctId":"NCT07457632","phase":"PHASE2","title":"Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional Chinese Medicine.","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Diabetic Macular Edema (DME)","enrollment":69},{"nctId":"NCT06755541","phase":"PHASE3","title":"Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-01-30","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":150},{"nctId":"NCT06415773","phase":"PHASE3","title":"Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2024-06-04","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":367},{"nctId":"NCT06350890","phase":"PHASE3","title":"Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2023-11-05","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":408},{"nctId":"NCT06922669","phase":"NA","title":"Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":"Drug Induced Liver Injury","enrollment":232},{"nctId":"NCT06610760","phase":"PHASE4","title":"Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2024-11-12","conditions":"Gastric Intestinal Metaplasia","enrollment":196},{"nctId":"NCT06353347","phase":"PHASE3","title":"Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2023-11-13","conditions":"Type 2 Diabetes Mellitus","enrollment":551},{"nctId":"NCT07005752","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).","status":"RECRUITING","sponsor":"Myungmoon Pharma. Co. Ltd.","startDate":"2025-07-28","conditions":"Cholesterol Cholelithiasis","enrollment":484},{"nctId":"NCT07068191","phase":"NA","title":"Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly","status":"RECRUITING","sponsor":"Phenomen Pharma","startDate":"2025-06-19","conditions":"Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL)","enrollment":90},{"nctId":"NCT07072949","phase":"PHASE1","title":"The Impact of Ursodeoxycholic Acid and Probiotics on Metabolic Outcomes in Type 2 Diabetic Patients Taking Metformin","status":"COMPLETED","sponsor":"University of Banja Luka","startDate":"2023-01-03","conditions":"Type 2 Diabetes Mellitus","enrollment":90},{"nctId":"NCT06060665","phase":"PHASE3","title":"Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-09-05","conditions":"Primary Biliary Cholangitis","enrollment":90},{"nctId":"NCT02961413","phase":"","title":"A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）","status":"RECRUITING","sponsor":"Drug Induced Liver Disease Study Group","startDate":"2016-04","conditions":"Drug-induced Liver Injury","enrollment":10000},{"nctId":"NCT06918080","phase":"PHASE4","title":"Hepatoprotective Measures for Children at High Risk of NAFLD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2023-11-19","conditions":"Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight, Acute Lymphoblastic Leukemia","enrollment":200},{"nctId":"NCT04924868","phase":"PHASE3","title":"Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis","status":"RECRUITING","sponsor":"Hospital General Universitario de Alicante","startDate":"2021-11-10","conditions":"Acute Pancreatitis Due to Gallstones","enrollment":332},{"nctId":"NCT02609048","phase":"PHASE2","title":"Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-11-04","conditions":"Primary Biliary Cirrhosis (PBC)","enrollment":41},{"nctId":"NCT05659654","phase":"PHASE1, PHASE2","title":"The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-12-16","conditions":"COVID-19","enrollment":95},{"nctId":"NCT04620733","phase":"PHASE3","title":"RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2021-04-21","conditions":"Primary Biliary Cholangitis","enrollment":193},{"nctId":"NCT06411275","phase":"PHASE2","title":"A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2022-03-31","conditions":"Type 2 Diabetes Mellitus","enrollment":113},{"nctId":"NCT03954327","phase":"PHASE2","title":"Combination Antiretroviral Therapy (cART) for PBC","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-03-01","conditions":"Primary Biliary Cholangitis","enrollment":37},{"nctId":"NCT05849558","phase":"PHASE4","title":"Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2022-02-22","conditions":"Chronic Liver Disease","enrollment":297},{"nctId":"NCT03602560","phase":"PHASE3","title":"ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-10-01","conditions":"Primary Biliary Cholangitis","enrollment":265},{"nctId":"NCT02955602","phase":"PHASE2","title":"Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-11-28","conditions":"Primary Biliary Cirrhosis","enrollment":119},{"nctId":"NCT03226067","phase":"PHASE2","title":"Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.","status":"COMPLETED","sponsor":"Calliditas Therapeutics AB","startDate":"2017-06-26","conditions":"Primary Biliary Cirrhosis","enrollment":111},{"nctId":"NCT02967250","phase":"PHASE1","title":"Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-04-01","conditions":"Parkinson Disease","enrollment":5},{"nctId":"NCT03844100","phase":"PHASE1, PHASE2","title":"Effectiveness and Safety in Administrating CNU® Capsule to Refractory Functional Dyspepsia Patients","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2019-11-01","conditions":"Dyspepsia, Biliary Dysplasia","enrollment":37},{"nctId":"NCT05043194","phase":"NA","title":"Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis","status":"UNKNOWN","sponsor":"Wei Liu","startDate":"2021-01-01","conditions":"Cholestasis of Parenteral Nutrition","enrollment":80},{"nctId":"NCT03678480","phase":"PHASE2","title":"A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)","status":"WITHDRAWN","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2021-03-01","conditions":"Primary Sclerosing Cholangitis, Cholangitis, Cholangitis, Sclerosing","enrollment":""},{"nctId":"NCT03664596","phase":"NA","title":"Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan","startDate":"2018-08-01","conditions":"Non-alcoholic Steatohepatitis","enrollment":80},{"nctId":"NCT04484870","phase":"PHASE4","title":"Danshu Capsule and Ursodeoxycholic Acid Capsule in Preventing Recurrence of Choledocholithiasis","status":"COMPLETED","sponsor":"First People's Hospital of Hangzhou","startDate":"2017-03-01","conditions":"Choledocholithiasis, Recurrence","enrollment":150},{"nctId":"NCT00746486","phase":"PHASE3","title":"Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)","status":"TERMINATED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2009-02","conditions":"Primary Biliary Cirrhosis","enrollment":62},{"nctId":"NCT02033876","phase":"PHASE2","title":"Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-10","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01510860","phase":"PHASE4","title":"Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2008-11","conditions":"Primary Biliary Cirrhosis","enrollment":65},{"nctId":"NCT03489889","phase":"NA","title":"Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2016-12","conditions":"Ursodeoxycholic Acid, Primary Biliary Cirrhosis","enrollment":30},{"nctId":"NCT03578055","phase":"PHASE3","title":"BDD With UDCA Therapy After Laparoscopic Cholecystectomy","status":"UNKNOWN","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2018-04-24","conditions":"Cholecystitis, Acute, Cholecystitis, Chronic","enrollment":172},{"nctId":"NCT02937012","phase":"PHASE3","title":"Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2016-10","conditions":"Primary Biliary Cirrhosis","enrollment":34},{"nctId":"NCT01899703","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-10","conditions":"Cholestasis, Intrahepatic","enrollment":22},{"nctId":"NCT01456468","phase":"PHASE1","title":"Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-10","conditions":"Cholangitis, Sclerosing","enrollment":19},{"nctId":"NCT01226823","phase":"PHASE3","title":"Ursodeoxycholic Acid And Cholestasis Of Pregnancy","status":"WITHDRAWN","sponsor":"University of Bologna","startDate":"2010-11","conditions":"Intrahepatic Cholestasis of Pregnancy","enrollment":""},{"nctId":"NCT01857284","phase":"PHASE3","title":"Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2009-09","conditions":"Primary Biliary Cirrhosis","enrollment":216},{"nctId":"NCT01073202","phase":"NA","title":"Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2005-05","conditions":"Liver Transplantation, Ischemia-reperfusion Injury, Cholestasis","enrollment":112}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"NEUTROPHIL COUNT DECREASED"},{"count":3,"reaction":"WHITE BLOOD CELL COUNT DECREASED"},{"count":2,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":2,"reaction":"ANAEMIA"},{"count":2,"reaction":"DEATH"},{"count":2,"reaction":"ELECTROLYTE IMBALANCE"},{"count":2,"reaction":"GASTROINTESTINAL DISORDER"},{"count":2,"reaction":"HYPERURICAEMIA"},{"count":2,"reaction":"HYPOKALAEMIA"},{"count":2,"reaction":"LYMPHOCYTE COUNT DECREASED"}],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ursofalk"],"phase":"phase_3","status":"active","brandName":"Ursodeoxycholic Acid Capsules","genericName":"Ursodeoxycholic Acid Capsules","companyName":"Beijing Friendship Hospital","companyId":"beijing-friendship-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ursodeoxycholic acid capsules are used to treat conditions such as ulcerative colitis, pouchitis, chronic cholecystitis, and acute pancreatitis due to gallstones, based on studies listed on ClinicalTrials.gov. The mechanism of action of ursodeoxycholic acid is related to secondary bile acids in intestinal inflammation, as per the study \"The Role of Secondary Bile Acids in Intestinal Inflammation\" on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}